Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has announced the publication in peer-reviewed journal Nature Medicine of 12-month data from its Phase 1 trial of AB-1002 investigational gene therapy in participants with congestive heart failure (CHF).1

Oct. 21, 2025 — GE HealthCare has received CE mark for its Carevance patient monitor, advancing accessible and reliable care for more customers starting in Europe. Carevance offers a clinically reliable and cost-effective solution with validated parameters and an intuitive, efficient workflow that can help empower care teams to stay focused on their patients.

Oct. 21, 2025 — At the seventeenth edition of the World Stroke Congress in Barcelona, Siemens Healthineers will present the Mobile Stroke Unit (MSU). This is the first mobile unit capable of diagnosing and treating stroke at the location where it occurs.

Oct. 20, 2025 – Brainomix, a provider of AI-powered imaging tools in lung fibrosis and stroke, will present new evidence at the CHEST Annual Meeting in Chicago showing its Brainomix 360 e-Lung technology could have significantly accelerated the diagnosis of Progressive Pulmonary Fibrosis (PPF) in over half of patients by up to almost two years.

Oct. 16, 2025 — Thirona recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for LungQ 4, the latest version of its AI-powered CT analysis software.

This new clearance builds on version 3 of LungQ, cleared by the FDA last year, which introduced advanced lung segmentation capabilities — a critical foundation for accurate analysis on a regional level. 

LungQ 4 extends these capabilities into:

Oct. 16, 2025 — Imbria Pharmaceuticals, has announced a partnership with the Hypertrophic Cardiomyopathy Association (HCMA), the leading advocacy group representing patients and families affected by hypertrophic cardiomyopathy. The partnership will accelerate patient recruitment and engagement in the ongoing Fortitude-HCM study, a Phase 2b clinical trial evaluating ninerafaxstat in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a debilitating disease with no currently approved treatments.

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the United States for the Synchrony system.

Oct. 15, 2025 — MedAxiom has released its 2025 Cardiovascular Provider Compensation and Production Survey report that includes data from the largest number of programs since its debut.

2025 MedAxiom Cardiovascular Provider Compensation and Production Survey report aggregates data on private vs. integrated practice, APP to physician ratios, patient volumes and subspeciality considerations.

Oct. 14, 2025 — Nurea has announced that its PRAEVAorta 2 software has received FDA 510(k) clearance, enabling entry into the U.S. market. PRAEVAorta 2 provides vascular physicians with the most advanced automated measurement tools for aortic diameters on contrasted and non-contrasted CT scans, supporting diagnosis and patient follow-up in aortic aneurysm management.

Oct. 13, 2025 — Medtronic plc recently announced it has received U.S. Food and Drug Administration (FDA) labeling approval1 for the Medtronic Endurant stent graft system, by adding ruptured abdominal aortic aneurysm (rAAA) clinical evidence and removing the rAAA treatment warning.

This FDA labeling approval makes Medtronic the first and only company to remove the rAAA warning from its stent graft system Instructions for Use (IFU), aligning innovation with real-world practices and training to empower physicians to act confidently in emergency cases.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now